Molecular Insight Shoots Up Overnight On Promising Cancer Trials
June 24, 2010 · Filed Under Cancer
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) was up $0.66 (41.25%) to $2.26 this morning on news that mid-stage trials of their cancer drug, Azedra, were going exceptionally well. Azedra would be used to treat neuroblastoma, a type of cancer which affects nerve tissue in children.
Molecular Insight Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutic and imaging radiopharmaceuticals for use in oncology.
Comments
Leave a Reply



